RVCL-S 循环内皮标志物研究
本研究测量了 3 个荷兰 RVCL-S 家系中 TREX1 突变携带者与健康对照的循环 VWF 抗原、VWF 前肽和血管生成素-2 水平,发现突变携带者上述标志物均升高,且在≥40 岁有临床表现者中效应最显著,提示内皮参与 RVCL-S 病理生理并可能作为疾病活动早期生物标志物。
要点
- TREX1 突变携带者 VWF 抗原、VWF 前肽和血管生成素-2 水平较非携带者及健康对照升高。
- ≥40 岁且有临床表现的突变携带者中标志物升高效应最显著。
- 上述标志物或可作为 RVCL-S 疾病活动的早期生物标志物。
核心结论
- 结果证实内皮在 RVCL-S 病理生理中起重要作用。
- VWF 抗原、VWF 前肽和血管生成素-2 可能作为疾病活动的早期生物标志物。
- 研究结果可能有助于理解卒中等常见神经血管疾病的病理生理。
研究设计与样本
- 测量 3 个荷兰 RVCL-S 家系成员及匹配的无关健康对照的循环 VWF 抗原、VWF 前肽和血管生成素-2 水平。
- TREX1 突变携带者 31 例,无 TREX1 突变的家庭成员 33 例,无关健康对照 31 例。
- 根据症状和年龄进行分层分析。
主要发现
- TREX1 突变携带者 VWF 抗原、VWF 前肽和血管生成素-2 水平较无突变家庭成员及无关健康对照升高(Kruskal-Wallis 检验 P<0.001)。
- ≥40 岁且有临床表现的突变携带者中效应最显著(Mann-Whitney U 检验 P<0.001)。
- 与健康对照相比,<40 岁突变携带者 VWF 抗原(P=0.02)和血管生成素-2(P=0.04)水平亦升高。
- 3 种标志物均与肾脏、肝脏疾病及炎症标志物呈中度相关。
临床怎么用
- 在 RVCL-S 患者中可考虑检测 VWF 抗原、VWF 前肽和血管生成素-2 以评估内皮受累和疾病活动。
- 上述标志物或有助于早期识别 TREX1 突变携带者的疾病活动。
局限性
- 研究样本来自 3 个荷兰家系,样本量有限,结果外推需谨慎。
- 原文未报告标志物与疾病活动纵向变化的关联。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: Retinal vasculopathy with cerebral leukoencephalopathy and systemic manifestations (RVCL-S) is a monogenic small vessel disease, caused by C-terminal truncating TREX1 mutations, that can be considered a model for stroke and vascular dementia. The pathophysiology of RVCL-S is largely unknown, but systemic endothelial involvement has been suggested, leading to pathology in the brain and other highly vascularized organs. Here, we investigated circulating endothelial markers to confirm endothelial involvement and identify biomarkers for disease activity. METHODS: We measured circulating levels of von Willebrand factor (VWF) antigen, VWF propeptide, and angiopoietin-2 in members of 3 Dutch RVCL-S families and matched unrelated healthy controls. Stratified analyses based on symptomatology and age were performed. RESULTS: We found elevated levels of VWF antigen, VWF propeptide, and angiopoietin-2 in TREX1 mutation carriers (n=31) compared with family members without a TREX1 mutation (n=33) and unrelated healthy controls (n=31; Kruskal-Wallis test P<0.001 for all comparisons). Effects were most pronounced in mutation carriers with clinical manifestations aged ≥40 years (Mann-Whitney U test P<0.001 for all comparisons). Compared with healthy controls, levels of VWF antigen (P=0.02) and angiopoietin-2 (P=0.04) were also elevated in mutation carriers aged <40 years. All 3 markers showed moderate correlations with markers of kidney and liver disease and inflammation (ie, systemic symptoms of RVCL-S). CONCLUSIONS: Our results confirm an important role of the endothelium in RVCL-S pathophysiology. VWF antigen, VWF propeptide, and angiopoietin-2 might serve as early biomarkers of disease activity. Our findings might also help to understand the pathophysiology of common neurovascular disorders, such as stroke.
引用
- Pelzer N, Bijkerk R, Reinders MEJ, et al. Circulating Endothelial Markers in Retinal Vasculopathy With Cerebral Leukoencephalopathy and Systemic Manifestations. Stroke. 2017. PMID: 29114091. doi:10.1161/STROKEAHA.117.018556
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。